DE60307106D1 - 9,11-cycloendoperoxyd prodrugs von prostaglandinanalogen für die behandlung von okularer hypertension und glaukoma - Google Patents

9,11-cycloendoperoxyd prodrugs von prostaglandinanalogen für die behandlung von okularer hypertension und glaukoma

Info

Publication number
DE60307106D1
DE60307106D1 DE60307106T DE60307106T DE60307106D1 DE 60307106 D1 DE60307106 D1 DE 60307106D1 DE 60307106 T DE60307106 T DE 60307106T DE 60307106 T DE60307106 T DE 60307106T DE 60307106 D1 DE60307106 D1 DE 60307106D1
Authority
DE
Germany
Prior art keywords
inanogenes
cycloendoperoxyd
prostagland
glaucoma
prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60307106T
Other languages
English (en)
Other versions
DE60307106T2 (de
Inventor
John Ling
Wu Yang
Jinsong Ni
Haiqing Yuan
D Tang-Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE60307106D1 publication Critical patent/DE60307106D1/de
Application granted granted Critical
Publication of DE60307106T2 publication Critical patent/DE60307106T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
    • C07D317/06—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60307106T 2002-08-05 2003-08-04 9,11-cycloendoperoxyd prodrugs von prostaglandinanalogen für die behandlung von okularer hypertension und glaukoma Expired - Fee Related DE60307106T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/212,437 US6864282B2 (en) 2002-08-05 2002-08-05 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
US212437 2002-08-05
PCT/US2003/024305 WO2004013119A1 (en) 2002-08-05 2003-08-04 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma

Publications (2)

Publication Number Publication Date
DE60307106D1 true DE60307106D1 (de) 2006-09-07
DE60307106T2 DE60307106T2 (de) 2007-02-22

Family

ID=31187772

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60307106T Expired - Fee Related DE60307106T2 (de) 2002-08-05 2003-08-04 9,11-cycloendoperoxyd prodrugs von prostaglandinanalogen für die behandlung von okularer hypertension und glaukoma

Country Status (9)

Country Link
US (1) US6864282B2 (de)
EP (2) EP1731516A3 (de)
JP (1) JP2005539014A (de)
AT (1) ATE334123T1 (de)
AU (1) AU2003261352A1 (de)
CA (1) CA2494146A1 (de)
DE (1) DE60307106T2 (de)
ES (1) ES2268433T3 (de)
WO (1) WO2004013119A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070768B2 (en) * 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US9241918B2 (en) 2005-03-16 2016-01-26 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
EP1916002B1 (de) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Verfahren zur prävention der zersetzung einer thermisch instabilen substanz
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
WO2012099942A2 (en) 2011-01-19 2012-07-26 Terakine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
US8778981B2 (en) 2012-11-21 2014-07-15 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
NO2753788T3 (de) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US9115109B2 (en) 2013-08-15 2015-08-25 Chirogate International Inc. Processes and intermediates for the preparations of isomer free prostaglandins
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
US11571401B2 (en) 2017-09-01 2023-02-07 East Carolina University Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4867915A (en) * 1986-05-21 1989-09-19 Syntex (U.S.A.) Inc. 16-Substituted polyunsaturated hexadecanoic fatty acids
ATE420857T1 (de) 1988-09-06 2009-01-15 Pfizer Health Ab Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
US5767154A (en) 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5385945A (en) 1992-10-21 1995-01-31 Allergan, Inc. 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
CA2274708A1 (en) 1997-10-13 1999-04-22 R-Tech Ueno, Ltd. Remedial composition for intraocular hypertension or glaucoma
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
ATE421595T1 (de) 2000-08-07 2009-02-15 Univ Vanderbilt Zusammensetzungen und verfahren zum nachweis und zur quantifizierung von cox-2-aktivität und 2- arachidonylglycerin-metaboliten

Also Published As

Publication number Publication date
EP1527063B1 (de) 2006-07-26
JP2005539014A (ja) 2005-12-22
EP1731516A3 (de) 2007-01-03
WO2004013119B1 (en) 2004-05-06
ES2268433T3 (es) 2007-03-16
CA2494146A1 (en) 2004-02-12
WO2004013119A1 (en) 2004-02-12
EP1731516A2 (de) 2006-12-13
AU2003261352A1 (en) 2004-02-23
US6864282B2 (en) 2005-03-08
EP1527063A1 (de) 2005-05-04
DE60307106T2 (de) 2007-02-22
US20040023954A1 (en) 2004-02-05
ATE334123T1 (de) 2006-08-15

Similar Documents

Publication Publication Date Title
ATE334123T1 (de) 9,11-cycloendoperoxyd prodrugs von prostaglandinanalogen für die behandlung von okularer hypertension und glaukoma
FI902258A0 (fi) Menetelmä farmakologisesti aktiivisten 13,14-dihydro-17-fenyyli-18,19,20-trinor-PGF2 -alkyyliestereiden valmistamiseksi
DE60334134D1 (de) Ungsmethode von erhöhtem augeninnendruck und glaukom
LU92509I2 (fr) Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN)
DE69634414D1 (de) Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
DK1039895T3 (da) Anvendelse af 3-benzoylphenyleddikesyrer, estere eller amider til behandling af GLC1A-glaukom
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
ATE223200T1 (de) Einen carboanhydrase-hemmer und xanthangummi enthaltendes augenarzneimittel
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
DE60003435D1 (de) Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
CA2364944A1 (en) C16 unsaturated fp-selective prostaglandins analogs
ATE216889T1 (de) Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension
DE69834638D1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
DE69829227D1 (de) Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
PT1051973E (pt) Agentes de melhoramento da circulacao optica papilar
AR023192A1 (es) Analogos de las flint resistentes a proteasas
PT91816A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de prostaglandinas para tratamento de glaucoma ou hipertensao ocular

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee